Tekmira Delays Start of Cancer Drug Trial, Sees Expanded Roche Partnership in '09 | GenomeWeb

Tekmira Pharmaceuticals this week announced that it has pushed back the expected start date for a phase I study of its siRNA-based cancer therapy PLK1 SNALP to some time in 2010 as it works to incorporate improvements in its drug-delivery technology into the program.

Meanwhile, the company continues to find success on the partnering front, announcing today that Bristol-Myers Squibb has exercised an option to extend its research collaboration with Tekmira through 2009.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PLOS this week: researchers explore the transfer of host genetic material into viruses, and more.

It's too difficult to correct or retract a flawed scientific paper, researchers write in Nature.

A proposed bill would require NSF to only fund research that's in "the national interest."

Australia's Commonwealth Scientific and Industrial Research Organisation plans to eliminate up to 350 jobs.